相关实验视频
Updated: May 28, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
基于网络的,以算法为指导的胰岛素定位在胰岛素治疗的2型糖尿病中:干预前后研究
Nishanth Thiagarajan1, Hong Chang Tan1, Suresh Rama Chandran1
1Department of Endocrinology, Singapore General Hospital, 20 College Road, Academia, Singapore, 169856, Singapore, 65 88900691.
这项研究表明,基于网络的糖尿病管理平台与算法引导的胰岛素定位显著改善了2型糖尿病患者的血糖控制. 高坚持性和轻度低血糖期表明其可行性用于例行护理.
科学领域:
- 内分泌学 在内分泌学.
- 数字健康数字健康
- 代谢疾病 代谢疾病
背景情况:
- 通过网络平台自我监测血糖 (SMBG) 对2型糖尿病 (T2D) 管理有希望.
- 在使用这些平台的亚洲人群中,算法引导胰岛素定位的有效性尚未得到充分研究.
研究的目的:
- 评估ALRT远程医疗解决方案的有效性和安全性,以改善胰岛素治疗T2D患者的血糖控制.
- 该ALRT解决方案将SMBG与算法驱动的胰岛素剂量调整集成在一起.
主要方法:
- 一项为期24周的前后干预研究,对25名患有T2D的成年人进行了每天两次预混合胰岛素的研究.
- 参与者使用移动应用程序上传SMBG数据,接受由医生审查的算法生成的胰岛素定位建议.
- 主要结局:血红蛋白A1c (HbA1c) 的变化;次要结局:空腹血葡萄糖,胰岛素剂量,低血糖和SMBG坚持.
主要成果:
- 从8.6%降低到7.4%的HbA1c显著降低 (P<.001).
- 禁食血葡萄糖显著下降 (P<.001).
- 高SMBG坚持 (97.3%);轻度低血糖事件增加,但没有发生严重事件.
结论:
- 基于网络的葡萄糖监测与算法指导的剂量显著改善了胰岛素治疗T2D的血糖控制.
- 高坚持表明日常护理的可行性,主要是轻微的低血糖症.
- 该干预措施对T2D管理具有前景,特别是在资源有限的环境中.
更多相关视频
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones